{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:31:09Z","timestamp":1768851069369,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) presents with diagnostic challenges due to symptom overlap with other gastrointestinal (GI) disorders. Recent studies identify anti-integrin \u03b1v\u03b26 autoantibodies as a promising biomarker for UC. This meta-analysis aims to evaluate the diagnostic accuracy of anti-integrin \u03b1v\u03b26 antibodies in distinguishing UC from healthy individuals and other GI diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic literature search of PubMed, Scopus, and Embase up to February, 2025, following PRISMA guidelines. Studies assessing the diagnostic performance of anti-integrin \u03b1v\u03b26 antibodies in UC patients were included. A bivariate random-effects model was used to pool sensitivity and specificity estimates using STATA. Forest plots and SROC curves were generated. Meta-regression and interaction analyses explored the influence of covariates such as control group type, age group, and geographic region on diagnostic performance. Risk of bias was assessed using tool QUADAS-2. Post hoc analyses were conducted to assess the impact of cut-off thresholds and ELISA platforms on the diagnostic performance of anti-integrin \u03b1v\u03b26 antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies comprising 3887 participants (1904 UC patients) were included in meta-analysis. The pooled sensitivity and specificity of anti-integrin \u03b1v\u03b26 for UC across all comparator groups were 83% (95% CI: 0.70\u20130.91) and 93% (95% CI: 0.88\u20130.97), respectively. Diagnostic performance remained consistent across control types for sensitivity but varied significantly for specificity, especially when Crohn\u2019s disease was used as a comparator (81%; 95% CI: 0.75\u20130.86). Multivariate meta-regression identified patient age, geographic region, and control group type as significant modifiers of specificity. Interaction models further confirmed a combined influence of these factors on diagnostic performance. Post hoc analyses revealed that sensitivity remained stable across thresholds (2SD: 0.65, 3SD: 0.87), while specificity varied significantly depending on cut-off values (2SD: 0.89, 3SD: 0.92) and ELISA methodology (0.92 vs. 0.83).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta-analysis demonstrates that anti-integrin \u03b1v\u03b26 antibodies exhibit high diagnostic accuracy for UC, with consistent sensitivity and specificity. Their performance is influenced by patient demographics and study region, suggesting the need for tailored diagnostic criteria in clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-025-02319-8","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:46:02Z","timestamp":1763005562000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic accuracy of anti-integrin \u03b1v\u03b26 in ulcerative colitis: a diagnostic meta-analysis"],"prefix":"10.1007","volume":"61","author":[{"given":"Mudasar","family":"Nisar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rafeh","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meher","family":"Ayyazuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Raza","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ahmad","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Abbas","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Humza","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu Baker","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2319_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389:1756\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"Lancet"},{"key":"2319_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/S41572-020-0205-X","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020. https:\/\/doi.org\/10.1038\/S41572-020-0205-X.","journal-title":"Nat Rev Dis Primers"},{"key":"2319_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2018","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2018;13:144-164K. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy113.","journal-title":"J Crohns Colitis."},{"key":"2319_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal Pouch disorders. J Crohns Colitis. 2017;11:649\u201370. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx008.","journal-title":"J Crohns Colitis."},{"key":"2319_CR5","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","volume":"160","author":"T Kuwada","year":"2021","unstructured":"Kuwada T, Shiokawa M, Kodama Y, Ota S, Kakiuchi N, Nannya Y, et al. Identification of an anti-integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis. Gastroenterology. 2021;160:2383-2394.e21. https:\/\/doi.org\/10.1053\/j.gastro.2021.02.019.","journal-title":"Gastroenterology."},{"key":"2319_CR6","doi-asserted-by":"publisher","unstructured":"Livanos AE, Dunn A, Fischer J, Ungaro RC, Turpin W, Lee S-H, et al. 826 Anti-integrin aVb6 autoantibodies are a novel predictive biomarker in ulcerative colitis. Gastroenterology. 2023;164:S-175. https:\/\/doi.org\/10.1016\/S0016-5085(23)01379-3","DOI":"10.1016\/S0016-5085(23)01379-3"},{"key":"2319_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.biocel.2018.04.013","volume":"99","author":"L Koivisto","year":"2018","unstructured":"Koivisto L, Bi J, H\u00e4kkinen L, Larjava H. Integrin \u03b1v\u03b26: structure, function and role in health and disease. Int J Biochem Cell Biol. 2018;99:186\u201396. https:\/\/doi.org\/10.1016\/j.biocel.2018.04.013.","journal-title":"Int J Biochem Cell Biol"},{"key":"2319_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cbin.10258","volume":"38","author":"Y Yu","year":"2014","unstructured":"Yu Y, Chen S, Lu G, Wu Y, Mo L, Liu Z, et al. Alphavbeta6 is required in maintaining the intestinal epithelial barrier function. Cell Biol Int. 2014;38:777\u201381. https:\/\/doi.org\/10.1002\/cbin.10258.","journal-title":"Cell Biol Int"},{"key":"2319_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.dld.2023.06.024","volume":"56","author":"I Marafini","year":"2024","unstructured":"Marafini I, Laudisi F, Salvatori S, Lavigna D, Venuto C, Giannarelli D, et al. Diagnostic value of anti-integrin \u03b1v\u03b26 antibodies in ulcerative colitis. Dig Liver Dis. 2024;56:55\u201360. https:\/\/doi.org\/10.1016\/j.dld.2023.06.024.","journal-title":"Dig Liver Dis"},{"key":"2319_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ."},{"key":"2319_CR11","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions|Cochrane Training. [cited 2023 Jun 12]. https:\/\/training.cochrane.org\/handbook. Accessed 12 Jun 2023."},{"key":"2319_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009.","journal-title":"Ann Intern Med"},{"key":"2319_CR13","volume-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2021","unstructured":"StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021."},{"key":"2319_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/BMJ.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557.","journal-title":"BMJ."},{"key":"2319_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos AE, Dunn A, Fischer J, Ungaro RC, Turpin W, Lee S-H, et al. Anti-integrin \u03b1v\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology. 2023;164:619\u201329. https:\/\/doi.org\/10.1053\/j.gastro.2022.12.042.","journal-title":"Gastroenterology"},{"key":"2319_CR16","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1053\/j.gastro.2022.06.026","volume":"163","author":"Y Muramoto","year":"2022","unstructured":"Muramoto Y, Nihira H, Shiokawa M, Izawa K, Hiejima E, Seno H, et al. Anti-integrin \u03b1v\u03b26 antibody as a diagnostic marker for pediatric patients with ulcerative colitis. Gastroenterology. 2022;163:1094-1097.e14. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.026.","journal-title":"Gastroenterology"},{"key":"2319_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00535-024-02176-x","volume":"60","author":"M Okabe","year":"2025","unstructured":"Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Yamazaki H, Nakanishi R, et al. Anti-integrin \u03b1v\u03b26 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study. J Gastroenterol. 2025;60:86\u201395. https:\/\/doi.org\/10.1007\/s00535-024-02176-x.","journal-title":"J Gastroenterol"},{"key":"2319_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071881","volume":"11","author":"N Rydell","year":"2022","unstructured":"Rydell N, Ekoff H, Hellstr\u00f6m PM, Mov\u00e9rare R. Measurement of serum IgG anti-integrin \u03b1v\u03b26 autoantibodies is a promising tool in the diagnosis of ulcerative colitis. J Clin Med. 2022;11:1881. https:\/\/doi.org\/10.3390\/jcm11071881.","journal-title":"J Clin Med"},{"key":"2319_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.advms.2023.09.010","volume":"68","author":"G Caliendo","year":"2023","unstructured":"Caliendo G, D\u2019Elia G, Makker J, Passariello L, Albanese L, Molinari AM, et al. Biological, genetic and epigenetic markers in ulcerative colitis. Adv Med Sci. 2023;68:386\u201395. https:\/\/doi.org\/10.1016\/j.advms.2023.09.010.","journal-title":"Adv Med Sci."},{"key":"2319_CR20","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.3748\/wjg.v30.i35.3954","volume":"30","author":"H Lv","year":"2024","unstructured":"Lv H, Li H-Y, Zhang H-N, Liu Y. Delayed diagnosis in inflammatory bowel disease: time to consider solutions. World J Gastroenterol. 2024;30:3954\u20138. https:\/\/doi.org\/10.3748\/wjg.v30.i35.3954.","journal-title":"World J Gastroenterol"},{"key":"2319_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.suc.2019.08.001","volume":"99","author":"S Flynn","year":"2019","unstructured":"Flynn S, Eisenstein S. Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am. 2019;99:1051\u201362. https:\/\/doi.org\/10.1016\/j.suc.2019.08.001.","journal-title":"Surg Clin North Am"},{"key":"2319_CR22","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3748\/wjg.v27.i20.2521","volume":"27","author":"FP N\u00fa\u00f1ez","year":"2021","unstructured":"N\u00fa\u00f1ez FP, Krugliak Cleveland N, Quera R, Rubin DT. Evolving role of endoscopy in inflammatory bowel disease: going beyond diagnosis. World J Gastroenterol. 2021;27:2521\u201330. https:\/\/doi.org\/10.3748\/wjg.v27.i20.2521.","journal-title":"World J Gastroenterol."},{"key":"2319_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000688","volume":"9","author":"W Waddingham","year":"2022","unstructured":"Waddingham W, Kamran U, Kumar B, Trudgill NJ, Tsiamoulos ZP, Banks M. Complications of diagnostic upper gastrointestinal endoscopy: common and rare\u2014recognition, assessment and management. BMJ Open Gastroenterol. 2022;9:e000688. https:\/\/doi.org\/10.1136\/bmjgast-2021-000688.","journal-title":"BMJ Open Gastroenterol"},{"key":"2319_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802\u201319. https:\/\/doi.org\/10.1038\/ajg.2015.120.","journal-title":"Am J Gastroenterol"},{"key":"2319_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228562","volume":"21","author":"A Finamore","year":"2020","unstructured":"Finamore A, Peluso I, Cauli O. Salivary stress\/immunological markers in Crohn\u2019s disease and ulcerative colitis. Int J Mol Sci. 2020;21:8562. https:\/\/doi.org\/10.3390\/ijms21228562.","journal-title":"Int J Mol Sci"},{"key":"2319_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1936315","author":"G Duvoisin","year":"2017","unstructured":"Duvoisin G, Lopez RN, Day AS, Lemberg DA, Gearry RB, Leach ST. Novel biomarkers and the future potential of biomarkers in inflammatory bowel disease. Mediators Inflamm. 2017. https:\/\/doi.org\/10.1155\/2017\/1936315.","journal-title":"Mediators Inflamm"},{"key":"2319_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0016-5085(98)70252-5","volume":"115","author":"FM Ruemmele","year":"1998","unstructured":"Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822\u20139. https:\/\/doi.org\/10.1016\/S0016-5085(98)70252-5.","journal-title":"Gastroenterology"},{"key":"2319_CR28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/GUT.42.6.788","volume":"42","author":"JF Quinton","year":"1998","unstructured":"Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae manna antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788\u201391. https:\/\/doi.org\/10.1136\/GUT.42.6.788.","journal-title":"Gut"},{"key":"2319_CR29","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/J.1572-0241.2006.00840.X","volume":"101","author":"GE Reese","year":"2006","unstructured":"Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410\u201322. https:\/\/doi.org\/10.1111\/J.1572-0241.2006.00840.X.","journal-title":"Am J Gastroenterol"},{"key":"2319_CR30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15899","volume":"20","author":"J Li","year":"2014","unstructured":"Li J. Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: a meta-analysis. World J Gastroenterol. 2014;20:15899. https:\/\/doi.org\/10.3748\/wjg.v20.i42.15899.","journal-title":"World J Gastroenterol"},{"key":"2319_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4203737","volume":"2018","author":"Z Xu","year":"2018","unstructured":"Xu Z, Wei B, Qiu Y, Zhang T. Altered salivary alpha-amylase secretion in patients with ulcerative colitis. Gastroenterol Res Pract. 2018;2018:1\u20136. https:\/\/doi.org\/10.1155\/2018\/4203737.","journal-title":"Gastroenterol Res Pract"},{"key":"2319_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/S13075-019-1815-0","volume":"21","author":"EC De Moel","year":"2019","unstructured":"De Moel EC, Derksen VFAM, Trouw LA, Bang H, Coll\u00e9e G, Lard LR. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Ther. 2019;21:28. https:\/\/doi.org\/10.1186\/S13075-019-1815-0.","journal-title":"Arthritis Res Ther"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02319-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:32:10Z","timestamp":1768473130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02319-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02319-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}